{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:08Z","timestamp":1787772368036,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To analyze the clinical trials that are registered on the Clinical Trial Registry of India (CTRI) portal for a year, for the treatment, prevention, and supportive therapy of coronavirus disease-19 (COVID-19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>All the trials registered on CTRI (since January 2020 till January 2021) for therapeutic, preventive, and supportive interventions for COVID-19 were searched with the keywords \u201cCoronavirus,\u201d \u201cCOVID-19,\u201d \u201cSARS-COV-2,\u201d and \u201c2019-nCoV\u201d. These registered studies were analyzed as follows: Trials under different systems of Medicine-Allopathy\/Homeopathy\/Ayurveda\/Unani\/Yoga\/Naturopathy. The Allopathy trials were further analyzed in detail: Intervention, design, comparator, number of subjects, duration, and approvals taken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>A total of 1597 records were found. After excluding the overlaps, behavioral and other studies conducted to understand the diagnosis, epidemiology, a total of 419 registered studies were included for further analysis. Out of these 419 studies, 166 (39.6%) were in Ayurveda, 154 (36.7%) in Allopathy, 33 (7.8%) in Homeopathy, 30 (7%) in Unani\/Siddha, 18 (4.3%) in Yoga and Naturopathy and 18 (4.3%) in Nutraceuticals. A total of 264 interventions had been registered in 419 clinical trials. Sixty-seven interventions were being studied under allopathy in 154 studies. Same product was being evaluated in differently designed protocols with different endpoints. Maximum number of trials and subjects were for Hydroxychloroquine 25 (17,998), Ivermectin 11 (2820), Convalescent Plasma 11 (3982), Remdesivir 8 (3725), Tocilizumab 6 (884), and Azithromycin 6 (582).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In response to the COVID-19 pandemic, Indian researchers came forward from all the systems of medicine to evaluate interventions for prophylaxis or treatment of the disease. The involvement of AYUSH systems of medicine was specifically more in this regard. A wide variation and heterogeneity in doses and outcomes were observed in trial designs which might make it difficult to generalize the study results when they are made available. Urgent analyses of studies involving interventions on the treatment advisory of the Government may help the healthcare providers take more informed decisions for managing COVID-19 patients in India.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_700_21","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:48:56Z","timestamp":1716479336000},"page":"258-269","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["In search for a panacea for coronavirus disease-19"],"prefix":"10.4103","volume":"54","author":[{"given":"Nidhi","family":"Maheshwari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-4-20240903","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s13337-021-00684-5","article-title":"Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: An update","volume":"32","author":"Sharma","year":"2021","journal-title":"Virusdisease"},{"key":"R3-4-20240903","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"R4-4-20240903","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"R5-4-20240903","doi-asserted-by":"crossref","first-page":"105998","DOI":"10.1016\/j.ijantimicag.2020.105998","article-title":"Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein","volume":"56","author":"Vankadari","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R6-4-20240903","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/0976-500X.142464","article-title":"Sofosbuvir: A novel treatment option for chronic hepatitis C infection","volume":"5","author":"Bhatia","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"key":"R7-4-20240903","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"R8-4-20240903","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12890-019-0968-6","article-title":"Ulinastatin treatment for acute respiratory distress syndrome in China: A meta-analysis of randomized controlled trials","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Pulm Med"},{"key":"R9-4-20240903","doi-asserted-by":"crossref","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-4-20240903","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40121-020-00325-2","article-title":"The pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection for COVID-19: Putting the cart before the horse","volume":"9","author":"Morrisette","year":"2020","journal-title":"Infect Dis Ther"},{"key":"R14-4-20240903","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with COVID-19","volume":"384","author":"Recovery Collaborative","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-4-20240903","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with COVID-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-4-20240903","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"R18-4-20240903","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(21)01064-3","article-title":"Convalescent plasma in patients hospitalised with COVID-19","volume":"397","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"R19-4-20240903","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14712598.2021.1905794","article-title":"A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19","volume":"21","author":"Kumar","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R20-4-20240903","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"R21-4-20240903","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/infdis\/jiab098","article-title":"A phase ii safety and efficacy study on prognosis of moderate pneumonia in coronavirus disease 2019 patients with regular intravenous immunoglobulin therapy","volume":"223","author":"Raman","year":"2021","journal-title":"J Infect Dis"},{"key":"R22-4-20240903","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijid.2021.03.015","article-title":"Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study","volume":"105","author":"Pandit","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R23-4-20240903","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00405-020-06402-z","article-title":"Topical lignocaine anaesthesia for oropharyngeal sampling for COVID-19","volume":"278","author":"Kanodia","year":"2021","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R24-4-20240903","doi-asserted-by":"crossref","first-page":"35","DOI":"10.31080\/ASOR.2021.04.0290","article-title":"Effect of 8.4% soda-bicarbonate steam inhalation on the course of disease in mild to moderate cases of COVID-19","volume":"4","author":"Mody","year":"2021","journal-title":"Acta Sci Orthop"},{"key":"R26-4-20240903","doi-asserted-by":"crossref","first-page":"000297","DOI":"10.23880\/MJCCS-16000297","article-title":"Randomized, comparative, clinical trial to evaluate efficacy and safety of PNB001 in moderate COVID-19 patients","volume":"5","author":"Lattmann","year":"2021","journal-title":"Med J Clin Trials Case Stud"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_700_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:40:23Z","timestamp":1787769623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_700_21"}},"subtitle":["Analysis of ongoing clinical trials for the management of coronavirus disease-19 pandemic in India"],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_700_21","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}